Patient no.	Age at Dx (years)	Sex	Histology	Metastasis	Treatment	Methylation subgroup (Fig 2A)	Chromosomal CNAs	Mutations	Disease status	Duration of FU (years)
SJPB08	7.63	F	PPTID	No	CCE x 2 → GTR CSI (23.4Gy) + tumor boost (total 54Gy) CCV x 4	PB-B	Loss: 11	NA	NED	4.03
SJPB14	14.80	M	PC	No	GTR	Control, pineal	Copy number neutral	NA	NED	1.28
SJPB16	4.71	M	Pineal anlage tumor	No	Bx → GTR CSI (23.4Gy) + tumor boost (total 54Gy) CCV x 4	ETMR	Gain: 8, 13q Focal gain: 2p, 10q Loss: 16q, 17p Focal/subarm loss: 6q, 10q, 11p, 14q, 19p	Somatic *DICER1* mutations: E1434fs + E1705K	DOD	1.32
SJPB50	7.21	M	PPTID	No	STR Focal proton (54Gy)	NA	NA	NA	SD	2.92
SJPB53	15.01	F	PPTID	No	Bx (residual > 1.5cm^2) CSI (36Gy) + tumor boost (total 55.8Gy) CCV (per ACNS0332 stratum A)	NA	NA	NA	SD	3.28
SJPB54	16.19	F	PTPR	No	STR (residual > 1.5cm^2) Focal RT (54Gy)	NA	NA	NA	SD	2.23

Bx, biopsy; CCE, carboplatin-cyclophosphamide-etoposide; CCV, cisplatin-cyclophosphamide-vincristine; CNAs, copy number alterations; CSI, craniospinal irradiation; DOD, died of disease; Dx, diagnosis; ETMR, embryonal tumor with multilayered rosettes; F, female; fs, frameshift; FU, follow-up; GTR, gross total resection; M, male; NA, data not available; NED, no evidence of disease; No., number; PB-B, pineoblastoma subgroup B; PC, pineocytoma, PPTID, pineal parenchymal tumor of intermediate differentiation; PTPR, papillary tumor of pineal region; RT, radiotherapy; STR, subtotal resection

Supplementary Table S1 Clinical characteristics, treatment, outcome and molecular features of patients with non-pineoblastoma histologies